$2.89
-0.09 (-3.02%)
Open$3.04
Previous Close$2.98
Day High$3.32
Day Low$2.85
52W High$74.50
52W Low$2.80
Volume—
Avg Volume430.2K
Market Cap67.11M
P/E Ratio—
EPS$-65.26
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,570.6% upside
Current
$2.89
$2.89
Target
$48.28
$48.28
$28.52
$48.28 avg
$57.13
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 35.77M | 36.63M | 30.48M |
| Net Income | -8,575,403 | -9,331,208 | -6,103,234 |
| Profit Margin | -24.0% | -25.5% | -20.0% |
| EBITDA | -11,561,063 | -12,252,085 | -10,099,093 |
| Free Cash Flow | -5,624,875 | -5,815,077 | -3,826,455 |
| Rev Growth | +23.1% | +18.9% | +13.6% |
| Debt/Equity | 0.47 | 0.46 | 0.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |